1. Emami J. In vitro – in vivo correlation: from theory to applications. J Pharm Pharmaceut Sci. 2006;9(2):31–51.
2. Food and Drug Administration. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations [Internet]. 1997. Available from: https://www.fda.gov/media/70939/download. Accessed 31 May 2019.
3. European Medicines Agency. Guideline on quality of oral modified release products [Internet]. 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf. Accessed 31 May 2019.
4. European Medicines Agency. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms [Internet]. 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf. Accessed 31 May 2019.
5. Nguyen MA, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J, et al. A survey on IVIVC/IVIVR development in the pharmaceutical industry—past experience and current perspectives. Eur J Pharm Sci. 2017;102:1–13. https://doi.org/10.1016/j.ejps.2017.02.029.